

NASPGHAN Annual Meeting & Postgraduate Course 2014

Advanced Endoscopy in Pediatric Populations

Field. F. Willingham, MD, MPH
 Director of Endoscopy
 Assistant Professor of Medicine




October 25, 2014

EMORY UNIVERSITY SCHOOL OF MEDICINE
 Interventional Endoscopy

EMORY HEALTHCARE
 REVEALING THE FUTURE

Objectives

- Recall the indications for advanced endoscopic procedures in Pediatric populations.
- Understand the applications and limitations of advanced endoscopic treatments applied to pediatric disease states.
- Understand the role, the outcomes, and the complications associated with the use of ERCP for pediatric presentations.
- Recall the new advances in the management of Barrett's esophagus.
- Understand the novel therapies for achalasia.



“

Moderation

is for monks.


Robert Heineken (1907-1988)

”





GERD SYMPTOMS IN CHILDREN




- Heartburn & regurgitation
- Apnea and/or bradycardia
- Poor appetite / weight loss / failure to thrive
- Wheezing, stridor
- Abdominal pain / chest pain
- Sore throat, hoarseness and/or laryngitis
- Water brash, cough, asthma, pneumonia



Neurologic impairment
Esophageal dysmotility, poor esophageal clearance
LES dysfunction
Hiatal hernia
Kyphoscoliosis
Muscle spasticity
Seizures
Recumbency
Decreased/absent verbal/motor responses to pain or chronic symptoms
Chronic lung disease
Chronic cough
Decreased intrathoracic pressure
Raised intra-abdominal pressure
LES dysfunction
Hiatal hernia
Prone, head-down position for chest PT
Decreased reporting of chronic symptoms (often regarded as "part of cystic fibrosis")
Repaired esophageal atresia
Dysmotility, poor esophageal clearance
Hiatal hernia
Chemotherapy for malignancies
Chemotherapy-induced severe mucositis of esophagus
Chronic/recurrent emesis
Hiatal hernia

Co-Morbidities in Childhood Barrett's Esophagus
Journal of Pediatric Gastroenterology and Nutrition, 25(3):255-260, September 1997.






16-year-old female referred with biopsy showing Barrett esophagus.

She has a history of diaphragmatic hernia, repaired in infancy.







Persistent reflux symptoms since birth, mostly controlled on a proton pump inhibitor.





Repair of her hiatal hernia with fundoplication 2010. Subsequently no symptoms on 30mg Prevacid once daily.



Questions for Patients	Quoted rates
With GERD, what are my chances of having BE?	14%
NDBE, chance of progressing to adenocarcinoma?	0.5% per year
How often to surveil in NDBE?	Q3 years
With HGD, what are my chances of progressing?	36% (6% per year)
Risk of stricture with RFA?	7%
Risk of mortality with esophagectomy?	Up to 10%

Am J Gastroenterol 2012; 107:1655-1661; Am J Gastroenterol 2012;107(4):534-542
Am J Gastroenterol (2000) 95, 1888-1893





POEM
Per Oral Endoscopic Myotomy





TABLE 8. Retrospective comparison of POEM and LHM (Chicago data)			
	POEM	LHM	P value
No. of patients	18	35	
Age, (range), y	38 (22-68)	49 (22-78)	.03
Prior achalasia treatment	None	None	
Anatomic type	Non-sigmoid	Non-sigmoid	
Sex, female/male	5/13	26/29	NS
Duration of symptoms, no. (range) y	1 (0-13)	1.25 (0.25-13)	NS
Operation time, no. (range) min	112 (69-220)	125 (90-190)	< .05
Estimated blood loss, no. (range) mL	≤ 10 in all cases	30 (10-200)	< .001
Myotomy length, no. (range) cm	9 (6-14)	8.5 (7-18)	NS
Pain score immediately postoperative (0-10, no. (range))	2.3 (0-6)	2 (0-9)	NS
Pain score 2 h postoperative, no. (range)	3.3 (0-6)	2 (0-10)	.03
Pain score on postoperative day 1, no. (range)	1.3 (0-4)	2 (0-10)	NS
Use of narcotics on the day of surgery (mg morphine equivalents)	8.3 (0-30)	6.7 (0-21.4)	NS
Use of narcotics on postoperative day 1	2.3 (0-7)	3.3 (0-16)	NS
Length of hospitalization, no. (range) d	1 (1-13)	1 (1-16)	NS
Minor adverse events, no. (%)	3 (17%)	7 (20%)	NS
Major adverse event	A contained leak at the GEJ requiring laparoscopic repair	Delayed esophageal leak requiring thoracotomy for drainage and repair	
Preoperative vs 6-wk postoperative LES basal and relaxation pressure (mmHg)	Basal: 19 (7-31) vs 9 (0-23) Relaxation: 21 (10-38) vs 12 (0-18)	Both .001	
Tissue barium esophagogram column heights at 1, 2, and 3 min postoperative vs leak postoperative, no.	17 vs 7 16 vs 5 14 vs 3	NS (≤ .06)	

POEM, Per-oral endoscopic myotomy; LHM, laparoscopic transhiatal myotomy; NS, not significant; GEJ, gastroesophageal junction; LES, lower esophageal sphincter.



Background

- Comparatively little data regarding endoscopic retrograde cholangiopancreatography (ERCP) in the pediatric population.
- Previous studies uncontrolled data & mixed diagnostic and therapeutic indications. In current practice, ERCP is primarily a therapeutic procedure.
- Purpose - to compare procedural variables, outcomes, and complications following therapeutic ERCP in pediatric patients versus an indication-matched adult control group.


Therapeutic ERCP in Children as Compared to Indication-Matched Adult Controls: A Four-Year Experience. Program No. P567. ACG 2013 Annual Scientific Meeting Abstracts. San Diego, CA: American College of Gastroenterology.



11 yo M presented for evaluation of a biliary stricture. H/o intermittent pruritis for two years.

H/o major traumatic ATV injury secondary to a motor cross accident, complicated by atlantooccipital dislocation and cervical spine fusion, renal injury resulting in left nephrectomy, acute pancreatitis.


Organic/Inorganic		
Glucose Serum		* 81 mg/dL
Blood Urea Nitrogen		10 mg/dL
Creatinine		0.53 mg/dL
Bilirubin Total		0.5 mg/dL
Bilirubin Direct		0.1 mg/dL
Bilirubin Indirect		0.4 mg/dL
Protein Total		6.8 gm/dL
Albumin Level		4.0 gm/dL
Calcium Level Total		9.6 mg/dL
BUN/Creat Ratio		19
Other Enzymes		
Alkaline Phosphatase		*H 457 unit/L
Alanine Aminotransferase		H 59 unit/L
Aspartate Aminotransferase		H 66 unit/L
Gamma Glutamyl Transferase		H 212 unit/L
Hemogram		
White Blood Count		L 4.4 10E3/mcL
Red Blood Cell Count		4.50 10E6/mcL
Hemoglobin		12.8 gm/dL
Hematocrit		37.1 %
MCV		82.4 fL
MCH		28.3 pg
MCHC		34.4 gm/dL
RDW		14.0 %


ERCP 1






ERCP 2






ERCP 3



Hepatic Function Panel (7)				
Protein, Total, Serum	7.1	g/dL	6.0 - 8.5	01
Albumin, Serum	4.5	g/dL	3.5 - 5.5	01
Bilirubin, Total	0.3	mg/dL	0.0 - 1.2	01
Bilirubin, Direct	0.06	mg/dL	0.00 - 0.40	01
Alkaline Phosphatase, S	340	U/L	150 - 530	01
AST (SGOT)	32	U/L	0 - 40	01
ALT (SGPT)	21	U/L	0 - 55	01
OUT	48	U/L	0 - 65	02

01	AT	LabCorp Tucker	Dir: John Elgin, MD
		1957 Lakeside Parkway Suite 542, Tucker, GA 30084-5882	
02	WB	LabCorp Birmingham	Dir: John Elgin, MD
		1801 First Avenue South, Birmingham, AL 35233-1935	

For inquiries, the physician may contact Branch: 770-939-4811 Lab: 770-939-4811



NASPGHAN Annual Meeting & Postgraduate Course 2014

Advanced Endoscopy in Pediatric Populations

Field. F. Willingham, MD, MPH
Director of Endoscopy
Assistant Professor of Medicine

October 25, 2014

 EMORY
UNIVERSITY
SCHOOL OF
MEDICINE
Interventional Endoscopy

 EMORY
HEALTHCARE
HEALTHCARE

A presentation slide for the NASPGHAN Annual Meeting & Postgraduate Course 2014. The slide features a black background with white text. The title is "Advanced Endoscopy in Pediatric Populations". The speaker is Field. F. Willingham, MD, MPH, Director of Endoscopy, Assistant Professor of Medicine. The date is October 25, 2014. The slide includes logos for Emory University School of Medicine and Emory Healthcare.